AI Stock Memo: BMY - Bristol-Myers Squibb - RankAlpha

BMY

AI Memo

Bristol-Myers Squibb

As of 2026-02-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-06 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Late-stage clinical readout / regulatory milestone (assumed window end) • 2026-12-31

Expected move: +1%

Biggest risk

Clinical failures, regulatory setbacks, accelerated generic/biosimilar erosion, or weaker guidance could push sentiment down to the bear target; litigation losses or margin pressure would deepen downside.

Invalidation

Break below $37 or thesis failure.

What would change my mind?

Successful late-stage readouts or favorable regulatory outcomes plus stable core product sales drive multiple expansion toward the analyst high; acquisition or clearer long-term guidance could lift the stock to the bull target.

Research note

Recommendation

—

Confidence

medium

As of

2026-02-06

Base target

$58

p=60%

Bull target

$68

p=20%

Bear target

$37

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Quarterly earnings and updated 2026 guidance
Patent, litigation or portfolio M&A developments
Successful late-stage readouts or favorable regulatory outcomes plus stable core product sales drive multiple expansion toward the analyst high; acquisition or clearer long-term guidance could lift the stock to the bull target.

BearKey bullets

Clinical trial failure or delay
Lower-than-expected sales or guidance
Patent expirations and biosimilar competition

WatchKey bullets

Late-stage clinical readout / regulatory milestone (assumed window end)

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $58 (p=60%)

Bull/Bear spread: +19% / -35%

Vs latest close: Bull +19% · Base +1% · Bear -35%

Scenario probabilities

Bull Target: $68 (p=20%)Base Target: $58 (p=60%)Bear Target: $37 (p=20%)

Commentary

Market consensus is broadly neutral-to-slightly-bearish with median targets near $57.68 while the anchor price trades at $59.51, indicating limited upside in the near term [#SERP-8] [#SERP-4]. Coverage shows a wide spread between low and high analyst views, reflecting binary pipeline and litigation risks [#SERP-3].

As of 2026-02-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Quarterly earnings and updated 2026 guidance
Patent, litigation or portfolio M&A developments

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-06Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$57.68

Range (USD)

$37.00 - $68.00

Count

Query: Bristol-Myers Squibb Co Common (BMY) analyst consensus price target high low average

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target
Search result #1
According to projections from 23 analysts, the average 12-month price target for Bristol-Myers Squibb is 58.04, with a high estimate of 68 and a low ...
Open source
Bristol-Myers Squibb Company (BMY) - Yahoo Finance
Search result #2
Bristol-Myers Squibb Company (BMY) Stock Price, News, Quote & History - Yahoo Finance ... Analyst Price Targets. 37.00 Low. 58.30 Average. 59.52 Current. 68.00 ...
Open source
Bristol-Myers Squibb Company (BMY) Stock Forecast, Price Targets ...
Search result #3
The average price target is $57.59 with a high forecast of $68.00 and a low forecast of $37.00. The average price target represents a 3.04% change from the last ...
Extracted: $57.59, $68.00, $37.00Open source
Bristol Myers Squibb Co. Analyst Estimates - BMY - MarketWatch
Search result #4
Bristol Myers Squibb Co. ; High, $68.00 ; Median, $60.00 ; Low, $37.00 ; Average, $57.68 ; Current Price, $55.99 ...
Extracted: $68.00, $60.00, $37.00, $57.68, $55.99Open source
Bristol Myers Squibb (BMY) Price Targets
Search result #5
The forecasts range from a low of $37.00 to a high of $68.00. The average price target represents an increase of 2.25% from the last closing price of $55.99.
Extracted: $37.00, $68.00, $55.99Open source
Bristol-Myers Squibb Company Stock Forecast | BMY Price Target ...
Search result #6
The highest price target is $66.00, while the lowest is $37.00. Compared to the current price of $54.58, this represents a potential 6.1% upside .
Extracted: $66.00, $37.00, $54.58Open source

Scenarios

Bull Target (Scenario probability)

$68 / p=20% prob

Base Target (Scenario probability)

$58 / p=60% prob

Bear Target (Scenario probability)

$37 / p=20% prob

Price $57 as of 2026-05-29

Nearest Scenario: Base (∆ 1%)

Targets vs latest close: Bull +19% · Base +1% · Bear -35%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-12-31
Late-stage clinical readout / regulatory milestone (assumed window end)
Potential Phase III readout or regulatory decision for a late-stage oncology/immunology asset; date uses conservative window end assumption and may move shares materially if outcome differs from expectations [#SERP-1]. Assumed window end for planning.
Prob 30.00% • Move 18.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Quarterly earnings and updated 2026 guidance
2026-05-07
Q4/FY2025 earnings release and management guidance update; market reaction likely if EPS/revenue or guidance diverges from consensus [#SERP-4]. Date conservatively estimated to allow filings and call prep.
Prob 70% • Move 6% • Priced-in 50%

Long-term Catalysts

Months to a year

Patent, litigation or portfolio M&A developments
2027-02-06
Potential litigation outcomes, biosimilar decisions, or strategic M&A that could re-rate valuation over a multi-quarter horizon; date set conservatively one year out [#SERP-2].
Prob 20% • Move 22% • Priced-in 30%

Risks

Clinical trial failure or delay
Lower-than-expected sales or guidance
Patent expirations and biosimilar competition
Regulatory adverse decision

Peers

Symbol	Summary
JNJ	Large diversified pharma with broad consumer/medtech exposure; defensive revenue mix compared with BMY's oncology focus.
MRK	Strong oncology and vaccine franchises; comparable regulatory risk profile but differing pipeline cadence.
PFE	Broad portfolio and manufacturing scale; more exposure to vaccine/cold-chain cycles affecting near-term guidance.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Bristol-Myers Squibb Co Common (BMY) analyst consensus price target high low average
Analysis date: 2026-02-06